Pharmacotherapy of social phobia. (Q35209664)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950437%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

review article

1 reference

title

Pharmacotherapy of social phobia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950437%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

0 references

J R T Davidson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950437%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950437%20AND%20SRC:MED&resulttype=core&format=json

Acta psychiatrica Scandinavica. Supplementum

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950437%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

417

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950437%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

65-71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950437%20AND%20SRC:MED&resulttype=core&format=json

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

The treatment of social phobia in general practice. is exposure therapy feasible?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Paroxetine in social anxiety disorder: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Treatment of social phobia with clonazepam and placebo.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

A repeat proton magnetic resonance spectroscopy study in social phobia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Treatment of social phobia with gabapentin: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Pharmacotherapy of Social Phobia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Moclobemide in social phobia: a controlled dose-response trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Placebo-controlled trial of moclobemide in social phobia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

The Brief Social Phobia Scale: a psychometric evaluation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Two-year follow-up of social phobias treated with Social Effectiveness Therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Nefazodone in social phobia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Nefazodone for social phobia: a clinical case series

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Social anxiety disorder in review: two decades of progress

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

A 2-year follow-up of social phobia. Status after a brief medication trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Discontinuation of clonazepam in the treatment of social phobia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Sertraline in children and adolescents with social anxiety disorder: an open trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Low dopamine D(2) receptor binding potential in social phobia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

Paroxetine for social anxiety and alcohol use in dual-diagnosed patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.108.S417.7.X

7 January 2021

10.1034/J.1600-0447.108.S417.7.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950437%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference